ClinicalTrials.gg
CompletedNCT05643794Updated Jul 1, 2025Results posted

A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome

A Phase 2 interventional study of rozanolixizumab and Placebo in Fibromyalgia, sponsored by UCB Biopharma SRL. Completed at 7 sites in United Kingdom. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Fibromyalgia with a site in United Kingdom — 4 open to participants now, 6 under way, none of them phase 3. Fibromyalgia · United Kingdom.

Enrollment
18th of 22
63 · median 266
Started
2022
with 1 other
Phase 2
5 of 31
none open now
Registered
23rd of 31
by date

Among the 31 studies in Fibromyalgia with a site in United Kingdom, this one is the 18th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 23rd registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

4 of the 31 studies in Fibromyalgia with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Fibromyalgia with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate efficacy and safety of rozanolixizumab to treat adult study participants with severe fibromyalgia syndrome (FMS).

03

Conditions studied

  • Fibromyalgia

Browse trials for

Keywords

  • Phase 2
  • Fibromyalgia
  • rozanolixizumab
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must be ≥18 years and ≤70 years of age at the time of signing the form (ICF)
  • Study participant with a diagnosis of fibromyalgia as defined by the 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria (American College of Rheumatology Preliminary

Diagnostic Criteria) plus the following characteristics during the Screening Period:

  1. Brief Pain Inventory-short form (BPI-SF) interference score ≥6.
  2. Study participant has been diagnosed with fibromyalgia syndrome (FMS) for at least 6 months.
  3. Study participant has been having FMS symptomatology for at least 2 years before enrollment - Capable of giving signed informed consent as described in the Protocol which includes compliance with the requirements and restrictions listed in the ICF and in the Study Protocol

Exclusion criteria

Exclusion Criteria:

  • Study participant has been diagnosed with fibromyalgia syndrome (FMS) for >15 years
  • Study participant has any systemic inflammatory disease
  • Study participant has any medical or psychiatric or separate chronic pain condition that, in the opinion of the investigator, could jeopardize or would compromise the study participant's ability to participate in this study or the ability to assess FMS-related pain
  • Study participant has severe renal impairment, defined as estimated \<30 mL/min/1.73 m\^2, (calculated using Modification of Diet in Renal Disease [MDRD] study equation), at Screening visit
  • Study participant has a active infection (including unresolved or not adequately treated infection) as assessed by the investigator
  • Study participant has chronic inflammatory demyelinating polyneuropathy
  • Study participant has a current or medical history of primary immunodeficiency
  • Study participant is pregnant or lactating
  • Study participant

    • Has suicide attempt in the past 2 years (including an active attempt, interrupted attempt, or aborted attempt),
    • OR had suicidal ideation with at least some intent to act in the past 6 months as indicated by a positive response (Yes) to either Question 4 or Question 5 of the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening or Baseline (Visit 3);
    • OR is otherwise judged clinically to be at a serious suicidal risk based on the investigator's judgment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Treatment sequence 1

    Study participants on Treatment sequence 1 will receive rozanolixizumab and Placebo during the dosing period at pre-specified timepoints.

    Drug: rozanolixizumab · Other: Placebo

  • Experimental
    Treatment sequence 2

    Study participants on Treatment sequence 2 will receive rozanolixizumab and Placebo during the dosing period at pre-specified timepoints.

    Drug: rozanolixizumab · Other: Placebo

  • Placebo comparator
    Treatment sequence 3

    Study participants on Treatment sequence 3 will receive Placebo during the dosing period at pre-specified timepoints.

    Other: Placebo

Interventions

  • Study participants will receive rozanolixizumab during the dosing periods as pre-defined.

    Also known as: UCB7665

  • OtherPlacebo

    Study participants will receive Placebo during the dosing periods as pre-defined.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Brief Pain Inventory Short Form (BPI-SF) Average Interference Score at 12 Weeks of Treatment

    The BPI-SF was a self-administered questionnaire used to evaluate the severity of a study participant's pain and the impact of this pain on the study participant's daily functioning. The BPI-SF assesses for the location of pain, pain intensity and functional interference from pain. The 7 BPI-SF interference items included: general activity, mood, walking ability, normal work (including housework), relations with other people, sleep, and enjoyment of life. Each item was rated on a 0 (did not interfere) to 10 (completely interfere) scale with a recall period of 24 hours. The BPI-SF interference score ranges 0-70. Higher scores indicated greater interference.

    Time frame: At 12 weeks of treatment

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. A TEAE was defined as any AE with an onset date on or after the first dose of investigational medicinal product (IMP) in Run-In and on or before the earliest of the following: the last date of infusion (including Run-Out) +56 days, final contact date, or death. A TEAE is also defined as any unresolved event already present before administration of treatment that worsens in intensity following exposure to the treatment.

    Time frame: From Baseline till end of Safety Follow-up (up to Week 33)

  2. Number of Participants With TEAEs Leading to Withdrawal of IMP

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. A TEAE was defined as any AE with an onset date on or after the first dose of IMP in Run-In and on or before the earliest of the following: the last date of infusion (including Run-Out) +56 days, final contact date, or death.

    Time frame: From Baseline till end of Safety Follow-up (up to Week 33)

  3. Brief Pain Inventory Short Form (BPI-SF) Average Interference Score at 24 Weeks of Treatment

    The BPI-SF was a self-administered questionnaire used to evaluate the severity of a study participant's pain and the impact of this pain on the study participant's daily functioning. The BPI-SF assesses for the location of pain, pain intensity and functional interference from pain. The 7 BPI-SF interference items included: general activity, mood, walking ability, normal work (including housework), relations with other people, sleep, and enjoyment of life. Each item was rated on a 0 (did not interfere) to 10 (completely interfere) scale with a recall period of 24 hours. The BPI-SF interference score ranges 0-70. Higher scores indicated greater interference.

    Time frame: At 24 weeks of treatment

  4. Revised Fibromyalgia Impact Questionnaire (FIQR) Score at 12 Weeks of Treatment

    The Revised Fibromyalgia Impact Questionnaire (FIQR) was a 21-item questionnaire with a recall period of 7 days. The FIQR included 3 domains: activities, overall impact, and symptoms. Each item was based on an 11-point numeric rating scale. The FIQR total score was calculated by taking the sum of the following: Activities domain subtotal divided by 3, overall impact" domain subtotal and symptoms domain subtotal divided by 2. The total score ranged from 0 to 100, with 0 denoting the best possible condition and 100 denoting the worst possible condition. Higher scores indicated more severe impact.

    Time frame: At 12 weeks of treatment

  5. Mean 7-day Average Daily Pain Score Assessed With Pain Numeric Rating Scale (NRS) at 12 Weeks of Treatment

    The Pain Numeric Rating Scale (NRS) was a scale in which a respondent selected a whole number that best described "How much pain have you experienced on average over the past 24 hours?" The 11-point Pain NRS ranged 0 (no pain) to 10 (pain as bad as you can imagine). Mean pain scores were derived the average of the daily assessment over the past 7 days. The higher score represented worst possible pain.

    Time frame: At 12 Weeks of treatment

  6. Mean 7-day Fatigue Score Assessed With Fatigue Numeric Rating Scale at 12 Weeks of Treatment

    The Fatigue Numeric Rating Scale (NRS) was a scale in which a respondent selected a whole number that best described "How much fatigue have you experienced on average over the past 24 hours?" The 11-point Fatigue NRS ranged 0 (no fatigue) to 10 (fatigue as bad as you can imagine). Mean fatigue scores were derived the average of the daily assessment over the past 7 days. Higher score represented worst possible fatigue.

    Time frame: At 12 weeks of treatment

07

Results

Posted Jul 1, 2025

Participant flow

The study started to enroll participants in December 2022 and concluded in July 2024.

Run-In (2 Weeks)
Participant flow — Run-In (2 Weeks)
MilestoneSequence 1: RLZ 12w + RLZ 12wSequence 2: PBO + RLZ 12wSequence 3: PBO + PBO
Started222021
Completed222021
Not completed000
Treatment Period 1 (12 Weeks)
Participant flow — Treatment Period 1 (12 Weeks)
MilestoneSequence 1: RLZ 12w + RLZ 12wSequence 2: PBO + RLZ 12wSequence 3: PBO + PBO
Started222021
Completed191920
Not completed311
Withdrew: Adverse event201
Withdrew: Lost to follow-up100
Withdrew: Consent withdrawn by study participant (not due to adverse event)010
Treatment Period 2 (12 Weeks)
Participant flow — Treatment Period 2 (12 Weeks)
MilestoneSequence 1: RLZ 12w + RLZ 12wSequence 2: PBO + RLZ 12wSequence 3: PBO + PBO
Started191920
Completed171820
Not completed210
Withdrew: Lack of efficacy010
Withdrew: Consent withdrawn by study participant (not due to adverse event)100
Withdrew: New work commitments100
Run-Out Period (2 Weeks)
Participant flow — Run-Out Period (2 Weeks)
MilestoneSequence 1: RLZ 12w + RLZ 12wSequence 2: PBO + RLZ 12wSequence 3: PBO + PBO
Started171820
Completed171820
Not completed000
Safety Follow-up Period (5 Weeks)
Participant flow — Safety Follow-up Period (5 Weeks)
MilestoneSequence 1: RLZ 12w + RLZ 12wSequence 2: PBO + RLZ 12wSequence 3: PBO + PBO
Started222021
Completed222021
Not completed000

Outcome measures

PrimaryBrief Pain Inventory Short Form (BPI-SF) Average Interference Score at 12 Weeks of Treatment

The BPI-SF was a self-administered questionnaire used to evaluate the severity of a study participant's pain and the impact of this pain on the study participant's daily functioning. The BPI-SF assesses for the location of pain, pain intensity and functional interference from pain. The 7 BPI-SF interference items included: general activity, mood, walking ability, normal work (including housework), relations with other people, sleep, and enjoyment of life. Each item was rated on a 0 (did not interfere) to 10 (completely interfere) scale with a recall period of 24 hours. The BPI-SF interference score ranges 0-70. Higher scores indicated greater interference.

Time frame:
At 12 weeks of treatment
Reported as:
Least squares mean · score on a scale
Brief Pain Inventory Short Form (BPI-SF) Average Interference Score at 12 Weeks of Treatment
score on a scalePlacebo (PBO)RLZ 12 Weeks
Brief Pain Inventory Short Form (BPI-SF) Average Interference Score at 12 Weeks of Treatment6.30 (5.59 to 7.01)5.76 (5.11 to 6.41)
Statistical analysis
  • Placebo (PBO) vs RLZ 12 Weeks · Longitudinal linear mixed effect model · p = 0.129 · Difference from placebo: -0.54 · 95% CI -1.24 to 0.16The difference presented is RLZ 12 weeks minus Placebo.
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. A TEAE was defined as any AE with an onset date on or after the first dose of investigational medicinal product (IMP) in Run-In and on or before the earliest of the following: the last date of infusion (including Run-Out) +56 days, final contact date, or death. A TEAE is also defined as any unresolved event already present before administration of treatment that worsens in intensity following exposure to the treatment.

Time frame:
From Baseline till end of Safety Follow-up (up to Week 33)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
ParticipantsRun-In-PBOTP1-RLZTP1-PBOTP2-RLZ/RLZTP2-PBO/RLZTP2-PBO/PBORun-Out and SFU-RLZ/RLZRun-Out and SFU-PBO/RLZRun-Out and SFU-PBO/PBO
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study442241181919101211
SecondaryNumber of Participants With TEAEs Leading to Withdrawal of IMP

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. A TEAE was defined as any AE with an onset date on or after the first dose of IMP in Run-In and on or before the earliest of the following: the last date of infusion (including Run-Out) +56 days, final contact date, or death.

Time frame:
From Baseline till end of Safety Follow-up (up to Week 33)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Withdrawal of IMP
ParticipantsRun-In-PBOTP1-RLZTP1-PBOTP2-RLZ/RLZTP2-PBO/RLZTP2-PBO/PBORun-Out and SFU-RLZ/RLZRun-Out and SFU-PBO/RLZRun-Out and SFU-PBO/PBO
Number of Participants With TEAEs Leading to Withdrawal of IMP031001002
SecondaryBrief Pain Inventory Short Form (BPI-SF) Average Interference Score at 24 Weeks of Treatment

The BPI-SF was a self-administered questionnaire used to evaluate the severity of a study participant's pain and the impact of this pain on the study participant's daily functioning. The BPI-SF assesses for the location of pain, pain intensity and functional interference from pain. The 7 BPI-SF interference items included: general activity, mood, walking ability, normal work (including housework), relations with other people, sleep, and enjoyment of life. Each item was rated on a 0 (did not interfere) to 10 (completely interfere) scale with a recall period of 24 hours. The BPI-SF interference score ranges 0-70. Higher scores indicated greater interference.

Time frame:
At 24 weeks of treatment
Reported as:
Least squares mean · score on a scale
Brief Pain Inventory Short Form (BPI-SF) Average Interference Score at 24 Weeks of Treatment
score on a scalePlaceboRLZ 24 Weeks
Brief Pain Inventory Short Form (BPI-SF) Average Interference Score at 24 Weeks of Treatment6.30 (5.59 to 7.01)5.79 (4.97 to 6.60)
Statistical analysis
  • Placebo vs RLZ 24 Weeks · Longitudinal mixed effects model · p = 0.358 · Difference from placebo: -0.51 · 95% CI -1.60 to 0.58The difference presented is RLZ 24 weeks minus PBO 24 weeks.
SecondaryRevised Fibromyalgia Impact Questionnaire (FIQR) Score at 12 Weeks of Treatment

The Revised Fibromyalgia Impact Questionnaire (FIQR) was a 21-item questionnaire with a recall period of 7 days. The FIQR included 3 domains: activities, overall impact, and symptoms. Each item was based on an 11-point numeric rating scale. The FIQR total score was calculated by taking the sum of the following: Activities domain subtotal divided by 3, overall impact" domain subtotal and symptoms domain subtotal divided by 2. The total score ranged from 0 to 100, with 0 denoting the best possible condition and 100 denoting the worst possible condition. Higher scores indicated more severe impact.

Time frame:
At 12 weeks of treatment
Reported as:
Least squares mean · score on a scale
Revised Fibromyalgia Impact Questionnaire (FIQR) Score at 12 Weeks of Treatment
score on a scalePlacebo (PBO)RLZ 12 Weeks
Revised Fibromyalgia Impact Questionnaire (FIQR) Score at 12 Weeks of Treatment70.70 (64.90 to 76.50)62.30 (57.32 to 67.28)
Statistical analysis
  • Placebo (PBO) vs RLZ 12 Weeks · Longitudinal mixed effects model · p = 0.003 · Difference from placebo: -8.40 · 95% CI -13.84 to -2.96The difference presented is RLZ 12 weeks minus Placebo
SecondaryMean 7-day Average Daily Pain Score Assessed With Pain Numeric Rating Scale (NRS) at 12 Weeks of Treatment

The Pain Numeric Rating Scale (NRS) was a scale in which a respondent selected a whole number that best described "How much pain have you experienced on average over the past 24 hours?" The 11-point Pain NRS ranged 0 (no pain) to 10 (pain as bad as you can imagine). Mean pain scores were derived the average of the daily assessment over the past 7 days. The higher score represented worst possible pain.

Time frame:
At 12 Weeks of treatment
Reported as:
Least squares mean · score on a scale
Mean 7-day Average Daily Pain Score Assessed With Pain Numeric Rating Scale (NRS) at 12 Weeks of Treatment
score on a scalePlaceboRLZ 12 Weeks
Mean 7-day Average Daily Pain Score Assessed With Pain Numeric Rating Scale (NRS) at 12 Weeks of Treatment6.59 (5.96 to 7.21)6.63 (6.09 to 7.18)
Statistical analysis
  • Placebo vs RLZ 12 Weeks · Longitudinal mixed effects model · p = 0.878 · Differences from placebo: 0.05 · 95% CI -0.55 to 0.64The differences presented is RLZ 12 weeks minus Placebo.
SecondaryMean 7-day Fatigue Score Assessed With Fatigue Numeric Rating Scale at 12 Weeks of Treatment

The Fatigue Numeric Rating Scale (NRS) was a scale in which a respondent selected a whole number that best described "How much fatigue have you experienced on average over the past 24 hours?" The 11-point Fatigue NRS ranged 0 (no fatigue) to 10 (fatigue as bad as you can imagine). Mean fatigue scores were derived the average of the daily assessment over the past 7 days. Higher score represented worst possible fatigue.

Time frame:
At 12 weeks of treatment
Reported as:
Least squares mean · score on a scale
Mean 7-day Fatigue Score Assessed With Fatigue Numeric Rating Scale at 12 Weeks of Treatment
score on a scalePlacebo (PBO)RLZ 12 Weeks
Mean 7-day Fatigue Score Assessed With Fatigue Numeric Rating Scale at 12 Weeks of Treatment7.26 (6.66 to 7.86)6.98 (6.45 to 7.51)
Statistical analysis
  • Placebo (PBO) vs RLZ 12 Weeks · Longitudinal mixed effects model · p = 0.352 · Difference from placebo: -0.28 · 95% CI -0.86 to 0.31The difference presented is RLZ 12 weeks minus Placebo.

Adverse events

Collected over From Baseline till end of Safety Follow-up (up to Week 33). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-In-PBO0/63 (0%)0/63 (0%)24/63 (38.1%)
TP1-RLZ0/22 (0%)0/22 (0%)21/22 (95.5%)
TP1-PBO0/41 (0%)3/41 (7.3%)37/41 (90.2%)
TP2-RLZ/RLZ0/18 (0%)0/18 (0%)18/18 (100%)
TP2-PBO/RLZ0/19 (0%)0/19 (0%)19/19 (100%)
TP2-PBO/PBO0/20 (0%)0/20 (0%)16/20 (80%)
Run-Out and SFU-RLZ/RLZ0/22 (0%)0/22 (0%)3/22 (13.6%)
Run-Out and SFU-PBO/RLZ0/20 (0%)1/20 (5%)8/20 (40%)
Run-Out and SFU-PBO/PBO0/21 (0%)2/21 (9.5%)3/21 (14.3%)
Most frequent serious events
Most frequent serious events
EventRun-In-PBOTP1-RLZTP1-PBOTP2-RLZ/RLZTP2-PBO/RLZTP2-PBO/PBORun-Out and SFU-RLZ/RLZRun-Out and SFU-PBO/RLZRun-Out and SFU-PBO/PBO
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/630/220/410/180/190/200/221/200/21
HeadacheNervous system disorders0/630/220/410/180/190/200/220/201/21
Back painMusculoskeletal and connective tissue disorders0/630/220/410/180/190/200/220/201/21
Respiratory syncytial virus bronchiolitisInfections and infestations0/630/221/410/180/190/200/220/200/21
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/630/221/410/180/190/200/220/200/21
Neck painMusculoskeletal and connective tissue disorders0/630/221/410/180/190/200/220/200/21
Most frequent other events
Showing 10 of 86
Most frequent other events
EventRun-In-PBOTP1-RLZTP1-PBOTP2-RLZ/RLZTP2-PBO/RLZTP2-PBO/PBORun-Out and SFU-RLZ/RLZRun-Out and SFU-PBO/RLZRun-Out and SFU-PBO/PBO
HeadacheNervous system disorders11/639/2217/414/187/193/200/224/200/21
DiarrhoeaGastrointestinal disorders4/633/223/411/187/191/200/220/200/21
Viral upper respiratory tract infectionInfections and infestations0/632/222/411/181/196/200/222/200/21
NasopharyngitisInfections and infestations0/635/226/414/182/192/200/220/200/21
NauseaGastrointestinal disorders11/634/224/413/184/193/200/220/200/21
Infusion site painGeneral disorders4/630/225/410/182/194/200/220/200/21
Upper respiratory tract infectionInfections and infestations0/630/226/410/180/194/202/220/202/21
HypersensitivityImmune system disorders0/634/220/411/181/190/200/220/200/21
Infusion site erythemaGeneral disorders0/630/220/410/183/190/200/220/200/21
ArthralgiaMusculoskeletal and connective tissue disorders0/631/222/410/183/192/200/220/200/21

Baseline characteristics

The Randomized Set (RS) included all enrolled participants who were randomized into the study.

Age, Categorical
Age, Categorical(Participants)Sequence 1: RLZ 12w + RLZ 12wSequence 2: PBO + RLZ 12wSequence 3: PBO + PBOTotal
<=18 years0000
Between 18 and 65 years21202061
>=65 years1012
Age, Continuous
Age, Continuous(years)Sequence 1: RLZ 12w + RLZ 12wSequence 2: PBO + RLZ 12wSequence 3: PBO + PBOTotal
Mean46.3 ± 9.947.8 ± 10.747.3 ± 9.547.1 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1: RLZ 12w + RLZ 12wSequence 2: PBO + RLZ 12wSequence 3: PBO + PBOTotal
Female21171755
Male1348
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sequence 1: RLZ 12w + RLZ 12wSequence 2: PBO + RLZ 12wSequence 3: PBO + PBOTotal
Asian0011
Black or African American0112
White22191960
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sequence 1: RLZ 12w + RLZ 12wSequence 2: PBO + RLZ 12wSequence 3: PBO + PBOTotal
Hispanic or Latino0011
Not Hispanic or Latino22202062
08

Study locations

7 sites
  • Fm0001 4405
    Blackpool, United Kingdom
  • Fm0001 4406
    Cannock, United Kingdom
  • Fm0001 4407
    Leeds, United Kingdom
  • Fm0001 4404
    Liverpool, United Kingdom
  • Fm0001 4402
    Manchester, United Kingdom
  • Fm0001 4403
    Stockton-on-Tees, United Kingdom
  • Fm0001 4401
    Tankersley, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in May 2024, 17 months.

Results were first posted in Jul 2025, 1 year 1 month after primary completion.

Of 24 phase 2 interventional studies under Fibromyalgia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Dec 9, 2022
StartActual
Dec 21, 2022
Primary completionActual
May 28, 2024
CompletionActual
Jul 9, 2024
Results first posted
Jul 1, 2025
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05643794
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Dec 9, 2022
Start date
Dec 21, 2022
Primary completion
May 28, 2024
Completion
Jul 9, 2024
Results posted
Jul 1, 2025
Last update
Jul 1, 2025

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rozanolixizumab

Start the discussion